Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Brain Region-Specific Peptide and Proteomic Signatures Inform Alzheimer's Disease Biomarker Panels.

Created on 06 Nov 2026

Authors

Mishael Sánchez-Pérez, José Pablo Osorio-Murillo, Adriana Martínez-Oviedo, Cesaré Ovando-Vázquez

Published in

Journal of proteome research. Volume 25. Issue 11. Pages 6356-6367. Nov 06, 2026.

Abstract

Alzheimer's disease (AD) is a heterogeneous neurodegenerative disorder with region- and severity-specific molecular signatures that complicate biomarker discovery. We combined peptide-centric quantitative proteomics data with machine learning, dimensionality reduction, nonlinear modeling, and network enrichment to identify candidate biomarkers across four brain regions and four AD severity stages. Dimensional reduction revealed disease-severity gradients (HCF-low ADNC → HCF-high ADNC → sporadic AD dementia (ADD) → autosomal-dominant AD) that were strongest in cortical regions (SMTG, IPL), moderate in the hippocampus, and weakest in the caudate. Machine-learning-based feature selection improved severity prediction, particularly at the peptide level, yielding panels of 10-22 region- and severity-specific biomarkers. Biomarker interaction modeling identified hubs centered on haptoglobin, VGF, APP, APOE, and midkine family members, partnering within neurosecretory, lipid transport, acute-phase response, and proteostasis pathways. STRING analysis validated these interactions, showing enrichment for secreted, hemoglobin-binding proteins with plasma and bone marrow tissue signals. Although biomarkers were predominantly region-specific, they converged on blood-linked pathways, supporting the translational potential of multi-marker, circulation-accessible panels. These findings show that peptide-level proteomics integrated with machine learning and network analysis clarifies AD heterogeneity and points to therapeutic avenues in neurovascular integrity, lipid transport, acute-phase response, and proteostasis, accelerating AD biomarker development.

PMID:
42992893
Bibliographic data and abstract were imported from PubMed on 06 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 12
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement